• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

The ‘don’t eat me’ an­ti­dote: Glax­o­SmithK­line, Roche and No­vo back $86M start­up in high-stakes CD47 show­down

9 years ago
R&D

Bind bur­ial com­plete, An­drew Hirsch lands the CFO’s job at high-pro­file Agios

9 years ago
People
Pharma

Hopes fad­ing, Onco­Genex ac­knowl­edges a PhI­II flop for can­cer drug

9 years ago
R&D

Sor­ren­to's new pain play­er Scin­til­la go­ing so­lo af­ter $200M buy­out deal

9 years ago
R&D

Ver­tex shut­ters a PhI­II cys­tic fi­bro­sis com­bo study, shares slip

9 years ago
R&D

Will some pent-up deal pres­sure amp up a biotech ral­ly?

9 years ago
R&D

Pro­to­cols: Bavar­i­an col­lab­o­rates with BMS on lung can­cer study; Eleven com­pletes Roche deal; In­tel­lia chief ...

9 years ago
R&D

Fac­ing ques­tions on pa­tient deaths, Au­rinia shares crater in wake of lu­pus study

9 years ago
R&D

FDA to Chi­as­ma on their Phase III re­jec­tion: Come up with a bet­ter plan next time

9 years ago
R&D

Work­ing to get its pain R&D strat­e­gy back on track, Acel­Rx steps clos­er to an FDA pitch

9 years ago
R&D

Zymeworks bags a pro­tein en­gi­neer­ing plat­form as it preps for an IPO

9 years ago
R&D

As­traZeneca gets a boost from dur­val­um­ab PhI­II chat­ter as pipeline wear and tear starts to show

9 years ago
R&D

Thumbs Up/Thumbs Down: The FDA backs an­oth­er R&D scheme, Kite shows its speed while Eli Lil­ly and As­tra stum­ble again

9 years ago
Bioregnum
Opinion

Biotech ven­ture cham­pi­on Bill Maris is ex­it­ing GV. What’s next?

9 years ago
R&D

Pro­to­cols: In­fin­i­ty hunts up a buy­er for its dis­ap­point­ing can­cer drug du­velis­ib; Is North­west Bio fi­nal­ly broke?

9 years ago
News Briefing

Start small, think big: Gen­mab racks up a bis­pe­cif­ic de­vel­op­ment deal with HIV spe­cial­ist Gilead

9 years ago
R&D

Pro­tag­o­nist’s IPO op­tion de­liv­ers a $90M pay­off for ear­ly-stage pep­tide work

9 years ago
R&D

The Brent Saun­ders way: Al­ler­gan pays $95M for its next step­ping stone to a big­ger pipeline

9 years ago
R&D

An­oth­er old drug looks for a sec­ond com­ing at the FDA, this time for Duchenne MD

9 years ago
R&D

Mi­cro­bio­me up­start Vedan­ta teams up with NYU Lan­gone sci­en­tist on check­point drugs

9 years ago
R&D

An in­tro­duc­tion to the End­points 100

9 years ago
Bioregnum
Opinion

As­traZeneca dou­bles down on Mod­er­na, in­vests $140M in $1.5B-plus biotech

9 years ago
R&D

Heron shares fly up af­ter FDA (fi­nal­ly) ap­proves its drug to rein in chemo side ef­fects

9 years ago
R&D

Frus­trat­ed Eli Lil­ly may have to set­tle for a lone­ly last-place fin­ish in the block­buster CDK 4/6 race

9 years ago
R&D
First page Previous page 1168116911701171117211731174 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times